Rutin as a Promising Inhibitor of Main Protease and Other Protein Targets of COVID-19: In Silico Study

Abstract

The process of investigating a possible cure for coronavirus disease 2019 (COVID-19) in vitro and in vivo may take a long time. For this reason, several in silico studies were performed in order to produce preliminary results that could lead to treatment. Extract of Juniperus procera Hochst is used as a traditional medicine for recovery from flu in Saudi Arabia. In the present study, more than 51 phytochemicals of J. procera were docked against the main protease of COVID-19. Rutin gave the highest interaction score among all the phytochemicals and the commercially available antiviral drugs. Lopinavir showed the second highest binding score. Rutin and lopinavir were further investigated using homology models of COVID-19. Rutin showed a better inhibition score in 9 of the 11 of homology models compared with lopinavir. Analysis of ligand-protein interaction contacts revealed that 3 residues (Glu166, Gly143, and Thr45) of the main protease formed hydrogen bonds with rutin. This simulation study suggests that rutin could be a possible effective inhibitor of several COVID-19 protein targets, including the main protease. Rutin, already available for commercial use, was evaluated for its ability as a possible drug. To our knowledge, this is the first study that suggests rutin having a possible strong inhibitory role against several protein targets of COVID-19.

Keywords

antiviral rutin lopinavir protein docking natural products

Coronaviruses are a family of viruses that are linked to several diseases in animals and humans. These diseases range from the common cold to more severe ones. At the end of December 2019, coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appeared in Wuhan City in China. No specific therapies are available for COVID-19 until now. COVID-19 symptoms are similar to those of common flu and in some cases can develop into pneumonia. At the time of writing this report, 5 704 736 cases and 357 736 deaths were confirmed by the World Health Organization (WHO) in 216 countries.

Juniperus procera Hochst (Arar) is one of more than 1200 medicinal plants found in Saudi Arabia.¹ Arar, found in the south of Saudi Arabia, is known for its possible ability for treating many diseases, including infections caused by viruses like the cold.^2
-4 The aim of this study was to investigate the possible inhibitory action of many phytochemicals of Arar against the solved crystal structure of the main protease of COVID-19 and 11 homology models of other proteins.

Results and Discussion

The results of docking indicate a strong possible interaction between rutin and the main protease enzyme, as shown in Table 1. Among 52 phytochemicals of Arar and 4 controls, rutin recorded the minimum binding energy of −136.47 indicating a strong interaction with the main protease. Supplemental Table S1 provides more details about the docked compounds. Rutin interacts with the main protease by forming several atomic contacts, as shown in Figure 1 and Supplemental Table S2. Ten hydrogen bonds were formed in the rutin-main protease complex compared with one found in 6-(ethylamino)pyridine-3-carbonitrile (RZS) (the native inhibitor)-main protease complex. This may explain the strong interaction between rutin and the main protease. For further confirmation, rutin was docked to the main protease using the COVID-19 Docking server; rutin gave a better inhibition effect than the other compounds. Further investigation was performed with rutin and lopinavir in order to know if these 2 compounds have an inhibition effect against potential targets of COVID-19 other than the main protease, as shown in Table 2. Rutin gave a better interaction score with 9 homology models of 11.

Table 1

Docking Score of Juniperus procera Phytochemicals, the Native Inhibitor, and Controls Against Main Protease of COVID-19.

Compound	Name	PubChem CID	iGemDock softwareScore	COVID-19 docking server score
Native inhibitor	RZS	24 701 445	−66	−4.90
Lopinavir	Control 1	92 727	−125.2	−8.40
Nelfinavir	Control 2	64 143	−116.94	−7.90
Ritonavir	Control 3	392 622	−111.4	−7.90
J. procera phytochemicals that gave best binding energy
1	Rutin	5 280 805	−136.47	−9.00
2	Deoxypodophyllotoxin	345 501	−101.09	−7.60
3	β-Peltatin A methyl ether	159 962	−106.85	−7.70
4	Quercetin	5 280 343	−87.88	−7.40
5	Isocupressic acid	6 438 138	−88.66	−6.20

Abbreviation: COVID-19, coronavirus disease 2019.

Figure 1

Docked compounds located in the binding pocket. Pink is the main protease, green is the native inhibitor, red is the docked inhibitor (it was almost superimposed with the relevant co-crystallized inhibitor indicating the accuracy of docking), orange is the lopinavir, and blue is the rutin. The box on the left presents the hydrogen bond contacts formed by rutin-main protease interaction.

Table 2

Docking Score of Rutin and Lopinavir Against Homology Models of COVID-19.

Protein target	COVID-19 docking server score
Protein target	Lopinavir	Rutin
Papain-like protease	−10.40	−9.70
RdRp with RNA	−9.40	−10.20
RdRp without RNA	−7.20	−9.00
Helicase ADP site	−6.80	−7.00
Helicase NCB site	−9.40	−9.60
Nsp14 (ExoN)	−7.50	−7.60
Nsp14 (N7-MTase)	−10.40	−10.50
Nsp15 (endoribonuclease)	−7.30	−7.50
Nsp16 (2′-O-MTase)	−8.00	−8.90
N protein NCB site	7.10	−8.50
E protein (ion channel)	−8.90	−8.70

Abbreviations: ADP, adenosine diphosphate; COVID-19, coronavirus disease 2019; NCB, non-competitive blockers; RdRp, RNA dependent RNA polymerase H; RNA, ribonucleic acid.

The molecular dynamics results showed that the root-mean-square deviation (RMSD) per residue of the X-ray structure of the main protease with no ligands was in a good agreement with the docked rutin-main protease complex (Figure 2). MD results revealed a nonsignificant difference in RMSD of all atoms of each residue pairs of the 2 comparing proteins. Based on MD results, the rutin-main protease complex is stable, and the ligand has no significant effect on the stability of the main protease.

Figure 2

RMSD per residue of the X-ray structure of DP4 (orange) and docked rutin-main protease (blue). RMSD indicates root-mean-square deviation.

Several in silico studies have examined the interaction between natural products and antiviral drugs with the main protease.^5

-8 However, no previous study has investigated the interaction between the constituents of J. procera with the main protease of COVID-19. More details about the possible importance of the main protease as an inhibition target of COVID-19 were presented by Khaerunnisa et al.⁶ Some studies have investigated the role of rutin as an inhibitor of other viruses. Dengue virus type-2 can be inhibited by rutin.⁹ A study by Lin et al¹⁰ reported the antiviral effects of rutin against the 3C protease of enterovirus A71 (EV-A71). Another study¹¹ observed the antiviral activity of rutin against herpes simplex virus type 1 in vitro. An extract of Euphorbia milii inhibited the growth of a ruminant virus. The study highlighted the possible link between the presence of rutin in the extract and the virus inhibition.¹²

Experimental

Protein Docking

The COVID-19 main protease crystal structure (protein data bank [PDB] ID: 5r82) was obtained from PDB, in pdb format. Chain A of the 5r82 structure was used for receptor preparation and docking. Homology models of COVID-19 based on the protein structures of SARS-CoV were used for rutin-protein docking, as shown in Table 2. The phytochemicals and other ligands were obtained from the PubChem database. Docking was carried out with iGEMDOCK 2.1 software¹³ and COVID-19 Docking server.¹⁴ Preparation of input files for docking was reported by¹⁵

Molecular Dynamics

Chain A of the main protease with no ligands and the docked rutin-main protease complex was used for the molecular dynamics (MD) study in order to investigate the effect of rutin on enzyme stability. MD simulation was performed using MDWeb.¹⁶ The MD simulation parameters and methods were previously reported.¹⁵

Conclusions

Rutin, a natural compound, showed a possible inhibition effect on the main protease and other key proteins in the life cycle of COVID-19. The use of a natural product as a treatment has its advantages over synthetic drugs in terms of reducing the side effects. Lopinavir showed the second highest interaction score after rutin and can be considered as a possible available drug for COVID-19. More in vitro and in vivo studies are needed for investigating this in silico study.

Supplemental Material

Supplementary Material 1. - Supplemental material for Rutin as a Promising Inhibitor of Main Protease and Other Protein Targets of COVID-19: In Silico Study

Supplemental material, Supplementary Material 1., for Rutin as a Promising Inhibitor of Main Protease and Other Protein Targets of COVID-19: In Silico Study by and Ateeq Ahmed Al-Zahrani in Natural Product Communications

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this work was supported financially by the Deanship of Scientific Research at Umm Al- Qura University (Grant Code. 18-SCI-1-01- 0028).

ORCID iD

Ateeq Ahmed Al-Zahrani

Supplemental Material

Supplemental material for this article is available online.

References

Samaha

HA.

Mansi

Abu-El-Halawa

. Antimicrobial, antiradical and xanthine oxidase inhibitory activities of Juniperus procera plant extracts from Albaha. World J Pharmacy Pharm Sci. 2017;6(2):232-242.

Ghazanfar

. Handbook of Arabian Medicinal Plants. Chemical Rubber Company (CRC) press; 1994.

Gashash

. Plants in Mountains of Sarah and Alhajaz. Albaha Uni Publisher; 2012.

Karunamoorthi

Girmay

Fekadu

. Larvicidal efficacy of Ethiopian ethnomedicinal plant Juniperus procera essential oil against Afrotropical malaria vector Anopheles arabiensis (Diptera: Culicidae). Asian Pac J Trop Biomed. 2014;4(Suppl 1):S99-S106.doi:10.12980/APJTB.4.2014C687

http://www.ncbi.nlm.nih.gov/pubmed/25183156

Chang

Y-C.

Tung

Y-A.

Lee

K-H

et al. Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking. 2020;Preprint. doi:10.20944/preprints202002.0242.v1

Khaerunnisa

Kurniawan

Awaluddin

Suhartati

Soetjipto

. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. 2020;Preprints. doi:10.20944/preprints202003.0226.v1

Shah

Modi

Sagar

. In silico studies on therapeutic agents for COVID-19: drug repurposing approach. Life Sci. 2020;252:117652. doi:10.1016/j.lfs.2020.117652

http://www.ncbi.nlm.nih.gov/pubmed/32278693

Sampangi-Ramaiah

MH.

Vishwakarma

Shaanker

. Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease. Curr Sci. 2020;118(7):1087-1092.

Keivan

Boon-Teong

Sing-Sin

Pooi-Fong

Mohd

RM.

Sazaly

. In vitro antiviral activity of fisetin, rutin and naringenin against dengue virus type-2. J Med Plants Res. 2014;8(6):307-312.doi:10.5897/JMPR11.1046

10.

Lin

Y-J.

Chang

Y-C.

Hsiao

N-W

et al. Fisetin and rutin as 3C protease inhibitors of enterovirus A71. J Virol Metho. 2012;182(1-2):93-98.doi:10.1016/j.jviromet.2012.03.020

http://www.ncbi.nlm.nih.gov/pubmed/22465253

11.

Boligon

AA.

Kubiça

TF.

Mario

et al. Antimicrobial and antiviral activity-guided fractionation from Scutia buxifolia Reissek extracts. Acta Physiologiae Plantarum. 2013;35(7):2229-2239.doi:10.1007/s11738-013-1259-0

12.

Chaman

Khan

FZ.

Khokhar

et al. Cytotoxic and antiviral potentials of Euphorbia milii var. splendens leaf against Peste des petits ruminant virus. Trop J Pharm Res. 2019;18(7):1507-1511.

13.

Hsu

K-C.

Chen

Y-F.

Lin

S-R.

Yang

J-M

. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics. 2011;12(Suppl 1):S33 doi:10.1186/1471-2105-12-S1-S33

http://www.ncbi.nlm.nih.gov/pubmed/21342564

14.

Kong

Yang

Xue

et al. COVID-19 Docking server: anServer: An interactive server for docking small molecules peptides and antibodies against potential targets of COVID-19. arXiv preprint 2020. arXiv:2003.00163.

15.

Al-Zahrani

. The potential inhibitory role of teucrolivins against human dipeptidyl peptidase 4 protein as a promising strategy for treatment of type 2 diabetes. Int J Compu Biol and Drug Desig. 2019;12(4):362 doi:10.1504/IJCBDD.2019.10025248

16.

Hospital

Andrio

Fenollosa

Cicin-Sain

Orozco

Gelpí

. MDWeb and MDMoby: an integrated web-based platform for molecular dynamics simulations. Bioinformatics. 2012;28(9):1278-1279.doi:10.1093/bioinformatics/bts139

http://www.ncbi.nlm.nih.gov/pubmed/22437851

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.31 MB

0.00 MB